Unnati Pharmax

Rybelsus Tablets
Composition: Semaglutide Tablets
Therapeutic Class: Oral GLP-1 Receptor Agonist (Antidiabetic)

Rybelsus is a high-quality oral formulation of Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the effective management of type 2 diabetes mellitus. It is the first oral GLP-1 therapy designed to provide powerful glycemic control along with additional metabolic benefits, including weight reduction and cardiovascular risk improvement.

Semaglutide works by stimulating glucose-dependent insulin secretion, suppressing excess glucagon release, delaying gastric emptying, and reducing appetite. This multi-mechanistic approach helps in achieving sustained blood glucose control while minimizing the risk of hypoglycemia when used appropriately.

Rybelsus Tablets are primarily indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It may be used as monotherapy or in combination with other antidiabetic agents to achieve optimal glycemic control, particularly in patients requiring advanced metabolic management.

Semaglutide tablets, Rybelsus oral GLP-1, type 2 diabetes treatment, weight-friendly diabetes medicine, antidiabetic tablets, pharmaceutical exporter India, and diabetes care medicine manufacturer India.

Rybelsus Tablets are manufactured under stringent WHO-GMP certified pharmaceutical standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for endocrinology clinics, hospitals, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.

Apigat 5 Tablets
Composition: Apixaban 5mg
Therapeutic Class: Oral Anticoagulant (Direct Factor Xa Inhibitor)

Apigat 5 Tablets contain Apixaban 5mg, a next-generation oral anticoagulant that selectively inhibits Factor Xa, a key component in the blood coagulation cascade. By blocking this enzyme, Apixaban effectively prevents the formation of harmful blood clots while maintaining a predictable and stable anticoagulant effect.

Apixaban is widely recognized for its favorable safety profile, reduced risk of major bleeding, and minimal need for routine coagulation monitoring compared to traditional anticoagulants. Apigat 5 offers convenient oral dosing with rapid onset of action, making it a preferred choice in long-term thromboembolic risk management.

Apigat 5 Tablets are primarily indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduction of the risk of recurrent thrombotic events. It is also used for thromboprophylaxis following orthopedic surgeries.

Apixaban 5mg tablets, Apigat 5, Eliquis alternative, oral blood thinner, Factor Xa inhibitor, stroke prevention medicine, DVT and PE treatment, cardiovascular medicines exporter India, and anticoagulant tablet manufacturer India.

Apigat 5 Tablets are manufactured under stringent GMP standards to ensure high purity, consistent potency, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiac care centers, pharmacies, government healthcare programs, and international pharmaceutical distributors.

Bosenlee 62.5 Tablets
Composition: Bosentan 62.5mg
Therapeutic Class: Endothelin Receptor Antagonist (ERA)

Bosenlee 62.5 Tablets contain Bosentan 62.5mg, a dual endothelin receptor antagonist that works by blocking the action of endothelin-1, a potent vasoconstrictor responsible for narrowing of blood vessels. By inhibiting endothelin receptors (ETA and ETB), Bosentan helps relax and widen pulmonary blood vessels, improving blood flow and reducing pulmonary arterial pressure.

Bosentan therapy significantly improves exercise capacity, delays disease progression, and enhances quality of life in patients suffering from pulmonary arterial hypertension (PAH). Bosenlee 62.5 offers a well-tolerated, oral treatment option with proven clinical benefits in both early and advanced stages of the disease.

Bosenlee 62.5 Tablets are primarily indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and slow clinical worsening. It is suitable for adult and pediatric patients as prescribed by healthcare professionals and is often used as part of long-term PAH management protocols.

Bosentan 62.5mg tablets, Bosenlee tablets, pulmonary arterial hypertension treatment, endothelin receptor antagonist, PAH oral therapy, cardiovascular specialty medicines, pharmaceutical exporter India, and Bosentan manufacturer India.

Bosenlee Tablets are manufactured in WHO-GMP certified facilities under strict quality and safety standards to ensure consistent potency, efficacy, and long-term stability. The product is supplied in tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for cardiology centers, pulmonology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Jardiance 25mg Tablets
Composition: Empagliflozin 25mg
Therapeutic Class: SGLT2 Inhibitor / Oral Antidiabetic Agent

Jardiance 25mg Tablets contain Empagliflozin 25mg, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood glucose levels by promoting glucose excretion through the kidneys. This insulin-independent mechanism effectively reduces plasma glucose, improves glycemic control, and offers additional cardiovascular and renal benefits.

Empagliflozin therapy is clinically proven to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. It also supports weight management, improves blood pressure, and offers renal protective effects, making Jardiance 25mg a comprehensive option for type 2 diabetes management.

Jardiance 25mg Tablets are primarily indicated for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise. It can be used as monotherapy or in combination with other antidiabetic agents to achieve optimal glycemic control.

Empagliflozin 25mg tablets, Jardiance 25mg, SGLT2 inhibitor, type 2 diabetes treatment, cardiovascular and renal protective antidiabetic medicine, pharmaceutical exporter India, and oral antidiabetic tablet manufacturer India.

Jardiance 25mg Tablets are manufactured under WHO-GMP certified facilities, ensuring high quality, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, pharmacies, government diabetes programs, and international pharmaceutical distributors.

Biypsa Lipaglyn Tablets
Composition: Saroglitazar Tablets
Therapeutic Class: Dual PPAR Agonist (Antidiabetic & Lipid-Modifying Agent)

Biypsa Lipaglyn is a high-quality oral formulation of Saroglitazar, a novel dual PPAR (Peroxisome Proliferator-Activated Receptor) agonist, designed to provide comprehensive management of diabetic dyslipidemia and metabolic disorders. It effectively addresses both elevated blood sugar and lipid abnormalities, offering a unique approach to improving cardiovascular and metabolic health in type 2 diabetes patients.

Saroglitazar works by activating PPAR-α and PPAR-γ receptors, leading to improved insulin sensitivity, decreased triglycerides, and better control of cholesterol profiles. This dual action helps reduce cardiovascular risk factors while optimizing glycemic control, making it particularly valuable in patients with type 2 diabetes associated with dyslipidemia.

Biypsa Lipaglyn Tablets are primarily indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus. It may be used alone or as an adjunct to other antidiabetic and lipid-lowering therapies to achieve comprehensive metabolic management.

Saroglitazar tablets, Lipaglyn, Biypsa Lipaglyn, diabetic dyslipidemia treatment, PPAR agonist tablets, antidiabetic and lipid-lowering medicine, pharmaceutical exporter India, and cardiovascular/metabolic medicine manufacturer India.

Biypsa Lipaglyn Tablets are manufactured in WHO-GMP certified facilities under stringent pharmaceutical and biologics quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for endocrinology clinics, hospitals, cardiometabolic care centers, government healthcare programs, and international pharmaceutical distributors.

Glyxambi Tablets
Composition: Empagliflozin + Linagliptin
Therapeutic Class: Oral Antidiabetic Combination (SGLT2 Inhibitor + DPP-4 Inhibitor)

Glyxambi Tablets contain a fixed-dose combination of Empagliflozin and Linagliptin, providing a dual mechanism to improve glycemic control in patients with type 2 diabetes mellitus. Empagliflozin, a selective SGLT2 inhibitor, lowers blood glucose by promoting renal excretion of glucose, while Linagliptin, a DPP-4 inhibitor, enhances incretin hormone activity to increase insulin secretion and reduce glucagon release in a glucose-dependent manner.

This complementary action results in effective control of both fasting and postprandial blood glucose levels, with the added benefits of cardiovascular and renal protection, weight neutrality, and a low risk of hypoglycemia. Glyxambi Tablets offer convenient once-daily oral administration, simplifying therapy for patients requiring combination treatment.

Glyxambi Tablets are primarily indicated for adults with type 2 diabetes mellitus who require additional glycemic control despite diet and exercise, especially in patients inadequately managed with either agent alone. The combination may also be used alongside other oral antidiabetic drugs for optimized therapy.

Empagliflozin + Linagliptin tablets, Glyxambi, SGLT2 and DPP-4 inhibitor combination, type 2 diabetes treatment, cardiovascular and renal protective antidiabetic therapy, pharmaceutical exporter India, and combination antidiabetic tablet manufacturer India.

Glyxambi Tablets are manufactured under WHO-GMP certified facilities, ensuring high quality, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, diabetes clinics, retail pharmacies, government health programs, and international pharmaceutical distributors.

Xarelto 20mg Tablet
Composition: Rivaroxaban 20mg
Therapeutic Class: Oral Anticoagulant (Direct Factor Xa Inhibitor)

Xarelto 20mg Tablet contains Rivaroxaban 20mg, a novel oral anticoagulant (NOAC) that works by selectively inhibiting Factor Xa, a key enzyme involved in the blood clotting cascade. This targeted mechanism helps prevent the formation of harmful blood clots while maintaining a predictable anticoagulant effect, reducing the need for routine coagulation monitoring.

Rivaroxaban offers rapid onset of action, consistent anticoagulation, and a convenient once-daily dosing regimen, making it a preferred alternative to traditional vitamin K antagonists. Xarelto 20mg is widely used in the prevention and treatment of thromboembolic disorders and has demonstrated strong efficacy and safety across multiple clinical settings.

Xarelto 20mg Tablet is primarily indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduction of the risk of recurrent thrombotic events. It is also prescribed in post-surgical settings to prevent venous thromboembolism following orthopedic procedures.

Rivaroxaban 20mg tablets, Xarelto anticoagulant, oral blood thinner, Factor Xa inhibitor, stroke prevention medicine, DVT and PE treatment, cardiovascular medicines exporter India, and anticoagulant tablet manufacturer India.

Xarelto Tablets are manufactured under stringent GMP standards, ensuring high purity, consistent potency, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiac care centers, pharmacies, government healthcare programs, and international pharmaceutical distributors.

Xarelto 20 mg Tablets
Composition: Rivaroxaban 20 mg Tablets
Therapeutic Class: Oral Anticoagulant (Direct Factor Xa Inhibitor)

Xarelto 20 mg is a high-quality formulation of Rivaroxaban, a novel oral anticoagulant (NOAC) designed for the effective prevention and treatment of thromboembolic disorders. It works by selectively inhibiting Factor Xa, a key enzyme in the blood coagulation cascade, thereby preventing the formation of harmful blood clots.

Rivaroxaban provides predictable anticoagulation with a rapid onset of action and does not require routine coagulation monitoring. Its fixed-dose regimen and minimal food and drug interactions make it a convenient and reliable option for long-term anticoagulation therapy.

Xarelto 20 mg Tablets are primarily indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), and reduction of the risk of recurrent thromboembolic events. It is also widely used in post-orthopedic surgery patients for thromboprophylaxis.

Rivaroxaban 20 mg tablets, Xarelto 20, oral anticoagulant tablets, blood thinner medicine, Factor Xa inhibitor, DVT and PE treatment, stroke prevention medicine, pharmaceutical exporter India, and anticoagulant manufacturer India.

Xarelto 20 mg Tablets are manufactured under stringent WHO-GMP certified standards to ensure consistent quality, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for cardiology clinics, hospitals, anticoagulation centers, government healthcare programs, and international pharmaceutical distributors.

Cidmus 200mg Tablets
Composition: Sacubitril 97mg + Valsartan 103mg (Equivalent to Sacubitril and Valsartan 200mg)
Therapeutic Class: Angiotensin Receptor-Neprilysin Inhibitor (ARNI) / Heart Failure Therapy

Cidmus 200mg Tablets contain a fixed-dose combination of Sacubitril and Valsartan, designed for the management of chronic heart failure with reduced ejection fraction (HFrEF). Sacubitril is a neprilysin inhibitor that increases levels of beneficial natriuretic peptides, promoting vasodilation and reducing fluid overload, while Valsartan is an angiotensin II receptor blocker (ARB) that helps lower blood pressure and decreases cardiac workload.

This dual-action therapy has been clinically proven to improve cardiovascular outcomes, reduce hospitalization rates for heart failure, and enhance overall quality of life in patients with HFrEF. Cidmus 200mg provides a convenient once- or twice-daily oral dosing regimen with consistent efficacy and tolerability.

Cidmus 200mg Tablets are primarily indicated for the treatment of symptomatic chronic heart failure (NYHA class II–IV) in adults with reduced ejection fraction. It is used as part of comprehensive heart failure management, alongside lifestyle modifications and other standard therapies.

Sacubitril and Valsartan 200mg tablets, Cidmus 200, ARNI therapy, HFrEF treatment, chronic heart failure management, cardiovascular medicines exporter India, and Sacubitril-Valsartan tablet manufacturer India.

Cidmus 200mg Tablets are manufactured in WHO-GMP certified facilities under strict quality and safety standards, ensuring consistent potency, efficacy, and stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, pharmacies, government heart care programs, and international pharmaceutical distributors.

Telvilite-80 AM Tablets
Composition: Telmisartan 40mg + Amlodipine 5mg
Therapeutic Class: Antihypertensive Combination (ARB + Calcium Channel Blocker)

Telvilite-80 AM Tablets contain a fixed-dose combination of Telmisartan 40mg, an angiotensin II receptor blocker (ARB), and Amlodipine 5mg, a calcium channel blocker (CCB). This combination provides dual-action blood pressure control by relaxing blood vessels, reducing vascular resistance, and improving blood flow.

Telmisartan helps block the effects of angiotensin II, lowering blood pressure and reducing strain on the heart, while Amlodipine relaxes arterial smooth muscles, controlling peripheral resistance and enhancing overall cardiovascular protection. The combination offers effective and sustained antihypertensive therapy with convenient once-daily dosing.

Telvilite-80 AM Tablets are primarily indicated for the management of essential hypertension in adults, particularly in patients who require combination therapy for improved blood pressure control. It may also help reduce the risk of cardiovascular events such as stroke, heart attack, and heart failure.

Telmisartan + Amlodipine tablets, Telvilite-80 AM, ARB + CCB combination, hypertension treatment, cardiovascular protection, oral antihypertensive medicine, pharmaceutical exporter India, and antihypertensive tablet manufacturer India.

Telvilite-80 AM Tablets are manufactured under WHO-GMP certified facilities following stringent quality and safety standards. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, pharmacies, government health programs, and international pharmaceutical distributors.

PRONPL 40 Tablets
Composition: Propranolol Hydrochloride IP 40 mg Tablets
Therapeutic Class: Non-Selective Beta-Adrenergic Blocker (Antihypertensive & Antianginal)

PRONPL 40 is a high-quality formulation of Propranolol, a non-selective beta-blocker widely used for the effective management of cardiovascular conditions such as hypertension, angina pectoris, and certain cardiac arrhythmias. It works by blocking beta-adrenergic receptors in the heart and blood vessels, reducing heart rate, cardiac output, and blood pressure.

Propranolol also decreases myocardial oxygen demand, making it an effective therapy for angina management. Additionally, it is used in the prevention of migraine, control of essential tremors, and management of certain forms of anxiety and hyperthyroidism-related symptoms, as per clinical guidance.

PRONPL 40 Tablets are primarily indicated for the treatment of hypertension, angina pectoris, cardiac arrhythmias, and secondary prevention following myocardial infarction. It may be used alone or in combination with other cardiovascular agents for optimal therapeutic outcomes.

Propranolol 40 mg tablets, PRONPL 40, beta-blocker tablets, antihypertensive medicine, heart care medicine, anti-anginal tablets, pharmaceutical exporter India, and cardiovascular medicine manufacturer India.

PRONPL 40 Tablets are manufactured in WHO-GMP certified facilities under stringent pharmaceutical quality standards to ensure consistent efficacy, safety, and stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, government healthcare programs, retail pharmacies, and international pharmaceutical distributors.

Indinol 1.5 Tablets
Composition: Indapamide 1.5mg (Sustained-Release)
Therapeutic Class: Thiazide-Like Diuretic / Antihypertensive

Indinol 1.5 Tablets contain Indapamide 1.5mg in a sustained-release formulation, a thiazide-like diuretic that helps lower blood pressure by promoting the excretion of sodium and water through the kidneys while retaining potassium to a greater extent than conventional diuretics. Indapamide also exhibits direct vascular effects, leading to arterial relaxation and improved peripheral resistance.

Indapamide therapy is clinically proven to effectively reduce systolic and diastolic blood pressure, decrease cardiovascular risk, and improve outcomes in patients with hypertension. The sustained-release formulation ensures once-daily dosing with stable plasma levels, minimizing fluctuations and improving patient compliance.

Indinol 1.5 Tablets are primarily indicated for the treatment of essential hypertension in adults. It may also be prescribed to manage edema associated with heart failure or other conditions as part of a physician-directed treatment regimen.

Indapamide 1.5mg SR tablets, Indinol 1.5, Lozol alternative, Natrilix equivalent, thiazide-like diuretic, hypertension treatment, cardiovascular protection medicine, pharmaceutical exporter India, and Indapamide sustained-release tablet manufacturer India.

Indinol 1.5 Tablets are manufactured under WHO-GMP certified facilities, ensuring high quality, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, pharmacies, government healthcare programs, and international pharmaceutical distributors.

Xilingio 25mg/5mg Tablets
Composition: Empagliflozin 25mg + Linagliptin 5mg Tablets
Therapeutic Class: Oral Antidiabetic Combination (SGLT2 Inhibitor + DPP-4 Inhibitor)

Xilingio 25mg/5mg is a high-quality fixed-dose combination of Empagliflozin and Linagliptin, designed to provide comprehensive glycemic control in patients with type 2 diabetes mellitus. This advanced dual-action formulation combines the benefits of an SGLT2 inhibitor (Empagliflozin) and a DPP-4 inhibitor (Linagliptin), delivering effective blood glucose reduction through complementary mechanisms.

Empagliflozin works by promoting glucose excretion through the kidneys, thereby lowering plasma glucose levels independently of insulin action, while also offering proven cardiovascular and renal benefits. Linagliptin enhances incretin hormone activity, increasing insulin secretion and reducing glucagon release in a glucose-dependent manner. Together, these agents provide sustained glycemic control with a low risk of hypoglycemia and neutral impact on body weight.

Xilingio 25mg/5mg Tablets are primarily indicated for the management of type 2 diabetes mellitus in adults, especially in patients who require combination therapy for improved glycemic control. It is suitable for use as an adjunct to diet and exercise and may be prescribed alone or in combination with other antidiabetic agents as per clinical guidelines.

Empagliflozin and Linagliptin tablets, Xilingio 25/5mg, type 2 diabetes combination therapy, SGLT2 and DPP-4 inhibitor tablets, oral antidiabetic exporter India, diabetes care medicines, and pharmaceutical tablet manufacturer India.

Xilingio Tablets are manufactured in WHO-GMP certified facilities under stringent quality standards to ensure consistent efficacy, safety, and stability. The product is supplied in export-grade, tamper-proof packaging with complete regulatory documentation, making it suitable for hospitals, clinics, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.

Udiliv 300 Tablets
Composition: Ursodeoxycholic Acid 300mg
Therapeutic Class: Bile Acid / Hepatoprotective Agent

Udiliv 300 Tablets contain Ursodeoxycholic Acid (UDCA) 300mg, a naturally occurring hydrophilic bile acid that helps improve bile flow and reduce the concentration of toxic bile acids in the liver. It works by dissolving cholesterol-rich gallstones, protecting liver cells, and improving overall liver function.

Ursodeoxycholic Acid is widely used in the management of various cholestatic liver diseases due to its cytoprotective, anti-inflammatory, and immunomodulatory properties. Udiliv 300 helps restore normal bile secretion, reduces liver enzyme levels, and prevents further liver damage, making it a cornerstone therapy in hepatology.

Udiliv 300 Tablets are primarily indicated for the treatment of primary biliary cholangitis (PBC), dissolution of cholesterol gallstones, and management of cholestatic liver disorders. It is also used in conditions such as non-alcoholic fatty liver disease (NAFLD), drug-induced liver injury, and biliary sludge, as prescribed by healthcare professionals.

Ursodeoxycholic Acid 300mg tablets, Udiliv 300, gallstone dissolution medicine, liver protection tablets, cholestatic liver disease treatment, hepatology medicines exporter India, and UDCA tablet manufacturer India.

Udiliv 300 Tablets are manufactured under stringent GMP standards to ensure high purity, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for gastroenterology clinics, hospitals, liver care centers, government health programs, and international pharmaceutical distributors.

Cidmus 100 mg Tablets
Composition: Sacubitril 50 mg + Valsartan 50 mg Tablets (Total 100 mg)
Therapeutic Class: Angiotensin Receptor-Neprilysin Inhibitor (ARNI) – Cardiovascular Medicine

Cidmus 100 mg is a high-quality oral formulation combining Sacubitril and Valsartan, specifically developed for the management of heart failure with reduced ejection fraction (HFrEF). This dual-action therapy provides enhanced cardiovascular protection by simultaneously inhibiting the renin-angiotensin system and enhancing natriuretic peptide activity, leading to improved cardiac function and reduced risk of hospitalization.

Sacubitril acts as a neprilysin inhibitor, increasing levels of beneficial natriuretic peptides, which promote vasodilation, diuresis, and reduction of cardiac remodeling. Valsartan, an angiotensin II receptor blocker (ARB), helps lower blood pressure and reduces strain on the heart by preventing harmful effects of angiotensin II. Together, they provide a comprehensive approach to managing chronic heart failure.

Cidmus 100 mg Tablets are primarily indicated for the treatment of adults with chronic heart failure (NYHA class II–IV) and reduced ejection fraction, aiming to improve symptoms, reduce hospitalization, and enhance survival.

Sacubitril and Valsartan tablets, Cidmus 100 mg, ARNI heart failure treatment, cardiovascular tablets, chronic heart failure medicine, antihypertensive and cardioprotective therapy, pharmaceutical exporter India, and cardiovascular medicine manufacturer India.

Cidmus 100 mg Tablets are manufactured in WHO-GMP certified facilities under stringent pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, heart failure care centers, government healthcare programs, and international pharmaceutical distributors.

Lonopin Pen Injection
Composition: Enoxaparin Sodium Injection (Prefilled Syringe/Pen)
Therapeutic Class: Low Molecular Weight Heparin (LMWH) Anticoagulant

Lonopin Pen is a high-quality formulation of Enoxaparin Sodium, a low molecular weight heparin (LMWH) widely used for the prevention and treatment of thromboembolic disorders. Designed for convenient and accurate subcutaneous administration, the Lonopin Pen ensures precise dosing and improved patient compliance.

Enoxaparin works by enhancing the activity of antithrombin III, selectively inhibiting Factor Xa and thrombin, thereby preventing the formation and extension of blood clots. It provides predictable anticoagulant effects with a lower risk of bleeding and reduced need for laboratory monitoring compared to unfractionated heparin.

Lonopin Pen Enoxaparin Injection is primarily indicated for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in high-risk patients, including those undergoing surgery or with prolonged immobilization. It is also used in the management of acute coronary syndromes (unstable angina and myocardial infarction), and for the treatment of existing thromboembolic conditions.

Enoxaparin injection pen, Lonopin Pen, LMWH anticoagulant, blood thinner injection, DVT and PE treatment, thrombosis prevention medicine, cardiovascular injectable, pharmaceutical exporter India, and anticoagulant manufacturer India.

Lonopin Pen is manufactured in WHO-GMP certified facilities under stringent pharmaceutical quality standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiac care units, orthopedic centers, government healthcare programs, and international pharmaceutical distributors.

CLOPIZEN A 75 Tablets
Composition: Clopidogrel 75mg + Aspirin 75mg Tablets
Therapeutic Class: Antiplatelet Combination Therapy

CLOPIZEN A 75 is a high-quality fixed-dose combination of Clopidogrel and Aspirin, formulated to provide effective dual antiplatelet therapy for the prevention of thrombotic cardiovascular events. This synergistic combination works by inhibiting platelet aggregation through two complementary pathways, significantly reducing the risk of blood clot formation.

Clopidogrel is a P2Y12 ADP receptor inhibitor that prevents platelet activation and aggregation, while Aspirin irreversibly inhibits cyclooxygenase (COX-1), reducing thromboxane A2 production. Together, they offer enhanced protection against atherothrombotic events compared to monotherapy.

CLOPIZEN A 75 Tablets are primarily indicated for the prevention of myocardial infarction, ischemic stroke, and other cardiovascular complications in patients with acute coronary syndrome (ACS), post-angioplasty, post-stent placement, and those at high risk of thrombotic events. It is widely prescribed for long-term cardiovascular risk management.

Clopidogrel and Aspirin tablets, CLOPIZEN A 75, dual antiplatelet therapy, cardiovascular medicines, stroke prevention tablets, heart care medicines, antithrombotic tablets, pharmaceutical exporter India, and antiplatelet tablet manufacturer India.

CLOPIZEN A 75 Tablets are manufactured in WHO-GMP certified facilities under stringent pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for cardiology clinics, hospitals, government healthcare programs, retail pharmacies, and international pharmaceutical distributors.

Primodil 5 mg Tablets
Composition: Amlodipine Besylate IP equivalent to Amlodipine 5 mg
Therapeutic Class: Calcium Channel Blocker (Antihypertensive & Antianginal)

Primodil 5 mg is a high-quality formulation of Amlodipine, a long-acting calcium channel blocker widely prescribed for the effective management of hypertension and angina pectoris. It works by relaxing and widening blood vessels, improving blood flow, and reducing the workload on the heart, thereby helping to maintain optimal cardiovascular health.

Amlodipine inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and a reduction in blood pressure. Its long duration of action ensures consistent 24-hour blood pressure control with once-daily dosing, improving patient compliance and treatment outcomes.

Primodil 5 mg Tablets are primarily indicated for the treatment of mild to moderate hypertension, chronic stable angina, and vasospastic (Prinzmetal’s) angina. It may be used alone or in combination with other antihypertensive agents as part of a comprehensive cardiovascular management plan.

Amlodipine 5 mg tablets, Primodil 5, blood pressure medicine, antihypertensive tablets, heart care medicine, calcium channel blocker tablets, pharmaceutical exporter India, and cardiovascular medicine manufacturer India.

Primodil 5 mg Tablets are manufactured in WHO-GMP certified facilities under strict quality control standards to ensure consistent potency, safety, and long-term stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.

Coversyl Tablets
Composition: Perindopril Erbumine
Therapeutic Class: Angiotensin-Converting Enzyme (ACE) Inhibitor

Coversyl Tablets contain Perindopril Erbumine, a long-acting ACE inhibitor that helps relax blood vessels by inhibiting the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor. This mechanism leads to reduced vascular resistance, improved blood flow, and effective control of blood pressure, thereby lowering the workload on the heart.

Perindopril is widely recognized for its cardioprotective properties and its ability to improve endothelial function. Coversyl provides consistent 24-hour blood pressure control, supports heart function, and helps prevent cardiovascular complications such as heart attack and stroke when used as part of a comprehensive treatment plan.

Coversyl Tablets are primarily indicated for the treatment of hypertension, heart failure, and stable coronary artery disease. It is also prescribed to reduce the risk of major cardiovascular events in patients with a history of myocardial infarction or revascularization procedures.

Perindopril Erbumine tablets, Coversyl brand, ACE inhibitor medicine, hypertension treatment, heart failure therapy, cardiovascular protection tablets, pharmaceutical exporter India, and antihypertensive manufacturer India.

Coversyl Tablets are manufactured under stringent GMP standards to ensure high quality, consistent potency, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.

Insugen Injection
Composition: Insulin Isophane 50% + Human Insulin 50%
Therapeutic Class: Intermediate-Acting / Short-Acting Insulin Combination

Insugen Injection contains a balanced combination of Insulin Isophane (50%) and Human Insulin (50%), providing both intermediate-acting and short-acting insulin effects. This formulation is designed to achieve optimal glycemic control by mimicking the body’s natural insulin release, helping manage both basal and postprandial blood glucose levels.

The short-acting Human Insulin component addresses immediate post-meal glucose spikes, while Insulin Isophane ensures sustained basal insulin coverage. Together, this combination helps maintain stable blood sugar levels throughout the day, improving overall diabetes management.

Insugen Injection is primarily indicated for the treatment of type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone are insufficient to control blood glucose. It is suitable for use in adults, adolescents, and children under medical supervision.

Insulin Isophane + Human Insulin injection, Insugen injection, intermediate-acting insulin, short-acting insulin, premixed insulin therapy, diabetes treatment injection, insulin therapy exporter India, and insulin manufacturer India.

Insugen Injection is manufactured under WHO-GMP certified facilities following stringent quality and safety standards. The product is supplied in sterile, tamper-proof, cold-chain compliant packaging with complete regulatory documentation, making it suitable for hospitals, diabetes clinics, insulin therapy centers, government healthcare programs, and international pharmaceutical distributors.

Glucobay 25mg Tablets
Composition: Acarbose 25mg
Therapeutic Class: Alpha-Glucosidase Inhibitor / Oral Antidiabetic Agent

Glucobay 25mg Tablets contain Acarbose 25mg, an oral antidiabetic agent that works by inhibiting alpha-glucosidase enzymes in the small intestine. This slows the breakdown of carbohydrates, resulting in a delayed and reduced postprandial rise in blood glucose levels.

Acarbose is especially effective in controlling post-meal hyperglycemia, improving overall glycemic control when used in combination with diet, exercise, and other antidiabetic medications. Glucobay 25mg provides a safe and well-tolerated therapy option with minimal systemic absorption and a low risk of hypoglycemia.

Glucobay 25mg Tablets are primarily indicated for the management of type 2 diabetes mellitus in adults, particularly in patients who require additional postprandial glucose control. It can be prescribed as monotherapy or in combination with other antidiabetic agents under medical supervision.

Acarbose 25mg tablets, Glucobay 25mg, alpha-glucosidase inhibitor, type 2 diabetes treatment, postprandial hyperglycemia control, oral antidiabetic medicine, pharmaceutical exporter India, and Acarbose tablet manufacturer India.

Glucobay 25mg Tablets are manufactured under WHO-GMP certified facilities, ensuring high quality, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, retail pharmacies, government diabetes programs, and international pharmaceutical distributors.

Glucobay 50 mg Tablets
Composition: Acarbose 50 mg Tablets
Therapeutic Class: Oral Antidiabetic (Alpha-Glucosidase Inhibitor)

Glucobay 50 mg is a high-quality oral formulation of Acarbose, an alpha-glucosidase inhibitor designed to help manage postprandial hyperglycemia in patients with type 2 diabetes mellitus. By delaying the breakdown and absorption of complex carbohydrates in the intestine, Glucobay helps prevent sharp spikes in blood glucose after meals.

Acarbose works locally in the gut to inhibit enzymes responsible for carbohydrate digestion, reducing post-meal glucose excursions while having minimal systemic absorption. This mechanism complements other antidiabetic therapies and contributes to improved overall glycemic control.

Glucobay 50 mg Tablets are primarily indicated for adults with type 2 diabetes mellitus, either as monotherapy when diet and exercise alone are insufficient or in combination with other oral antidiabetic agents to achieve optimal glycemic control.

Acarbose tablets, Glucobay 50 mg, alpha-glucosidase inhibitor, postprandial blood sugar management, oral antidiabetic tablets, diabetes treatment medicine, pharmaceutical exporter India, and antidiabetic tablet manufacturer India.

Glucobay 50 mg Tablets are manufactured in WHO-GMP certified facilities under strict pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, diabetes clinics, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.

Cipdapla 10mg Tablets
Composition: Dapagliflozin 10mg
Therapeutic Class: SGLT2 Inhibitor / Oral Antidiabetic Agent

Cipdapla 10mg Tablets contain Dapagliflozin 10mg, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood glucose levels by promoting urinary glucose excretion. By reducing renal glucose reabsorption, Dapagliflozin improves glycemic control independently of insulin, while also providing cardiovascular and renal benefits.

Dapagliflozin therapy is associated with reduced risk of heart failure hospitalization, improved kidney function, and favorable effects on body weight and blood pressure. Cipdapla 10mg offers a convenient once-daily oral dosing regimen, making it a valuable option for the management of type 2 diabetes mellitus.

Cipdapla 10mg Tablets are primarily indicated for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise. It may be prescribed as monotherapy or in combination with other antidiabetic agents to achieve optimal glycemic control.

Dapagliflozin 10mg tablets, Cipdapla 10mg, SGLT2 inhibitor, type 2 diabetes treatment, oral antidiabetic medicine, cardiovascular and renal protective diabetes therapy, pharmaceutical exporter India, and antidiabetic tablet manufacturer India.

Cipdapla 10mg Tablets are manufactured under WHO-GMP certified facilities, ensuring high quality, consistent efficacy, and long-term stability. The product is supplied in secure, tamper-evident, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, clinics, pharmacies, government diabetes programs, and international pharmaceutical distributors.

Soluble Insulin Injection I.P. (Human Actrapid)
Composition: Human Insulin I.P. (Soluble)
Therapeutic Class: Short-Acting Insulin (Antidiabetic Injectable)

Soluble Insulin Injection I.P., marketed under the brand Actrapid, is a high-quality, short-acting human insulin formulation designed for the effective management of type 1 and type 2 diabetes mellitus. It provides rapid control of blood glucose levels, mimicking the natural insulin response after meals.

Actrapid works by facilitating the uptake of glucose into muscle and fat cells while inhibiting hepatic glucose production. This short-acting insulin begins to act within 30 minutes, peaks between 2–4 hours, and lasts up to 8 hours, making it ideal for pre-meal glucose control and adjustment of basal insulin regimens.

Soluble Insulin Injection is primarily indicated for the management of hyperglycemia in patients with type 1 diabetes and in type 2 diabetes when oral antidiabetic agents alone are insufficient. It may also be used in combination with intermediate-acting or long-acting insulin for optimized glycemic control.

Human insulin injection, Soluble Insulin I.P., Actrapid, short-acting insulin, antidiabetic injectable, blood sugar control injection, pharmaceutical exporter India, and insulin manufacturer India.

Soluble Insulin Injection I.P. is manufactured in WHO-GMP certified facilities under stringent biologics and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, cold-chain compliant, tamper-proof packaging with complete regulatory documentation, making it suitable for hospitals, diabetes clinics, endocrinology centers, government healthcare programs, and international pharmaceutical distributors.

Victoza (Liraglutide) Injection
Composition: Liraglutide Injection
Therapeutic Class: GLP-1 Receptor Agonist – Antidiabetic Injectable

Victoza is a high-quality injectable formulation of Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for the effective management of type 2 diabetes mellitus. It helps achieve sustained glycemic control while offering additional benefits such as weight reduction and improved cardiovascular outcomes. Victoza is also marketed under the brand name Saxenda for weight management in appropriate patients.

Liraglutide works by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. This multi-mechanistic action helps control blood sugar levels effectively and supports metabolic health with a reduced risk of hypoglycemia.

Victoza Liraglutide Injection is primarily indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It may be used alone or in combination with other antidiabetic therapies to achieve optimal glycemic control. Saxenda is indicated for chronic weight management in adults with obesity or overweight with associated comorbidities.

Liraglutide injection, Victoza, Saxenda, GLP-1 receptor agonist, antidiabetic injectable, weight management injectable, pharmaceutical exporter India, and antidiabetic biologics manufacturer India.

Victoza Injection is manufactured in WHO-GMP certified facilities under stringent pharmaceutical and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, endocrinology and diabetes clinics, obesity management centers, government healthcare programs, and international pharmaceutical distributors.

Hctzide 25 mg Tablets
Composition: Hydrochlorothiazide 25 mg Tablets
Therapeutic Class: Thiazide Diuretic (Antihypertensive)

Hctzide 25 mg is a high-quality formulation of Hydrochlorothiazide, a thiazide diuretic widely used for the effective management of hypertension and fluid retention (edema). It works by increasing the excretion of sodium and water through the kidneys, reducing blood volume, and lowering blood pressure, thereby supporting cardiovascular health.

Hydrochlorothiazide promotes diuresis and helps control elevated blood pressure, making it a first-line therapy in patients with mild to moderate hypertension. It may also be used to manage edema associated with congestive heart failure, liver cirrhosis, and chronic kidney disease, either alone or in combination with other antihypertensive agents.

Hctzide 25 mg Tablets are primarily indicated for the treatment of high blood pressure and fluid retention. They are suitable for long-term therapy and can be used alone or as part of combination therapy to achieve optimal blood pressure control and cardiovascular risk reduction.

Hydrochlorothiazide tablets, Hctzide 25 mg, thiazide diuretic tablets, blood pressure medicine, edema management tablets, antihypertensive tablets, pharmaceutical exporter India, and cardiovascular medicine manufacturer India.

Hctzide 25 mg Tablets are manufactured in WHO-GMP certified facilities under stringent pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The product is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, cardiology clinics, retail pharmacies, government healthcare programs, and international pharmaceutical distributors.